Loading...
XNASAKTX
Market cap123kUSD
Dec 20, Last price  
0.97USD
1D
-2.99%
1Q
-69.88%
Jan 2017
-86.22%
IPO
-98.81%
Name

Akari Therapeutics PLC

Chart & Performance

D1W1MN
XNAS:AKTX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-20.90%
Rev. gr., 5y
%
Revenues
0k
Net income
-10m
L+43.54%
-675,000-2,119,000-1,435,000-3,620,000-9,648,000-45,317,532-18,140,997-27,923,992-19,950,000-21,764,000-17,597,000-17,606,856-6,972,252-10,008,000
CFO
-16m
L-23.59%
-366,000-1,008,000-2,134,000-5,450,000-9,461,000-4,965,583-24,624,535-31,598,709-22,536,000-12,257,000-16,951,000-18,846,528-21,504,522-16,432,000

Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
URL
https://www.akaritx.com/
IPO date
Jan 31, 2014
Employees
15
Domiciled in
US
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
23,488
23,088
17,214
Unusual Expense (Income)
NOPBT
(23,488)
(23,088)
(17,214)
NOPBT Margin
Operating Taxes
(10,776)
183
Tax Rate
NOPAT
(23,488)
(12,312)
(17,397)
Net income
(10,008)
43.54%
(6,972)
-60.40%
(17,607)
0.06%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,020
25,194
14,293
BB yield
-4,597.01%
-171,749.72%
-44,400.06%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
947
4,305
Net debt
(3,845)
(13,250)
(9,361)
Cash flow
Cash from operating activities
(16,432)
(21,505)
(18,847)
CAPEX
Cash from investing activities
Cash from financing activities
7,020
25,288
14,293
FCF
(23,245)
(12,312)
(17,397)
Balance
Cash
3,845
13,250
9,361
Long term investments
Excess cash
3,845
13,250
9,361
Stockholders' equity
(174,983)
(217,479)
(199,770)
Invested Capital
174,754
219,270
205,325
ROIC
ROCE
10,256.77%
EV
Common stock shares outstanding
4,894
3,122
2,146
Price
0.03
563.97%
0.00
-68.67%
0.02
-18.92%
Market cap
153
941.02%
15
-54.43%
32
10.16%
EV
(3,692)
(13,235)
(9,329)
EBITDA
(23,484)
(23,084)
(17,210)
EV/EBITDA
0.16
0.57
0.54
Interest
5,340
Interest/NOPBT